{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:10:31Z","timestamp":1793661031445,"version":"4.5.1"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejmech.2025.117834","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:05:00Z","timestamp":1748862300000},"page":"117834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A medicinal chemistry perspective on ATR: Current status and future directions"],"prefix":"10.1016","volume":"296","author":[{"given":"Kun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guogang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117834_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117834_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib3","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117834_bib4","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117834_bib5","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/cells9071665","article-title":"DNA damage: from threat to treatment","volume":"9","author":"Carusillo","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117834_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrc3342","article-title":"The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance","volume":"12","author":"Bouwman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117834_bib7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.molonc.2014.10.013","article-title":"Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer","volume":"9","author":"Abdel-Fatah","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117834_bib8","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","article-title":"Biomarker-guided development of DNA repair inhibitors","volume":"78","author":"Cleary","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib10","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.2741\/4866","article-title":"Evolution of PIKK family kinase inhibitors: a new age cancer therapeutics","volume":"25","author":"Shaik","year":"2020","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.ejmech.2025.117834_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2237209","article-title":"Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)","volume":"38","author":"Huang","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib12","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.2741\/4867","article-title":"Structural and strategic landscape of PIKK protein family and their inhibitors: an overview","volume":"25","author":"Angira","year":"2020","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.ejmech.2025.117834_bib13","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.trecan.2021.06.002","article-title":"Targeting the replication stress response through synthetic lethal strategies in cancer medicine","volume":"7","author":"Ngoi","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2025.117834_bib14","first-page":"108","article-title":"A mitosis-specific and R loop-driven ATR pathway promotes faithful chromosome segregation","volume":"359","author":"Kabeche","year":"2018","journal-title":"Sci. Technol. Humanit."},{"key":"10.1016\/j.ejmech.2025.117834_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117834_bib17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.currproblcancer.2017.05.002","article-title":"Targeting ATR in cancer medicine","volume":"41","author":"Sundar","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.ejmech.2025.117834_bib18","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117834_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib20","first-page":"196","article-title":"Sequential administration of XPO1 and ATR inhibitors enhances therapeutic response in TP53-mutated colorectal cancer","volume":"161","author":"Inoue","year":"2021","journal-title":"Gastroenterology (New York, N. Y., 1943)"},{"key":"10.1016\/j.ejmech.2025.117834_bib21","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3390\/genes12060925","article-title":"Kinase inhibitors of DNA-PK, ATM and ATR in combination with ionizing radiation can increase tumor cell death in HNSCC cells while sparing normal tissue cells","volume":"12","author":"Faulhaber","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2025.117834_bib22","doi-asserted-by":"crossref","first-page":"15167","DOI":"10.1073\/pnas.0504981102","article-title":"Drosophila ATM and ATR checkpoint kinases control partially redundant pathways for telomere maintenance","volume":"102","author":"Bi","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.117834_bib23","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117834_bib24","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1158\/1541-7786.MCR-20-0651","article-title":"Exploiting replication stress as a novel therapeutic intervention","volume":"19","author":"Martin","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117834_bib27","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1111\/cas.15845","article-title":"Emerging strategies for cancer therapy by ATR inhibitors","volume":"114","author":"Yano","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.117834_bib28","doi-asserted-by":"crossref","first-page":"11488","DOI":"10.1021\/acs.jmedchem.4c00113","article-title":"New Horizons of synthetic lethality in cancer: current development and future perspectives","volume":"67","author":"Previtali","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib29","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.3390\/molecules27082491","article-title":"Recent advances in synergistic antitumor effects exploited from the inhibition of ataxia telangiectasia and RAD3-Related protein kinase (ATR)","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules (Basel)"},{"key":"10.1016\/j.ejmech.2025.117834_bib30","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1073\/pnas.93.7.2850","article-title":"cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein","volume":"93","author":"Cimprich","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.117834_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103662","article-title":"Targeting ATM and ATR for cancer therapeutics: inhibitors in clinic","volume":"28","author":"Priya","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.117834_bib32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41419-020-03090-9","article-title":"ATRIP protects progenitor cells against DNA damage in vivo","volume":"11","author":"Matos-Rodrigues","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.117834_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0968-0004(00)01563-2","article-title":"FAT: a novel domain in PIK-related kinases","volume":"25","author":"Bosotti","year":"2000","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2025.117834_bib34","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1101\/gad.1666208","article-title":"TopBP1 activates ATR through ATRIP and a PIKK regulatory domain","volume":"22","author":"Mordes","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2025.117834_bib35","doi-asserted-by":"crossref","first-page":"15741","DOI":"10.1074\/jbc.M513172200","article-title":"The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM","volume":"281","author":"Jiang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cr.2017.158","article-title":"Cryo-EM structure of human ATR-ATRIP complex","volume":"28","author":"Rao","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib37","first-page":"1206","article-title":"3.9 A structure of the yeast Mec1-Ddc2 complex, a homolog of human ATR-ATRIP","volume":"358","author":"Wang","year":"2017","journal-title":"Sci. Technol. Humanit."},{"key":"10.1016\/j.ejmech.2025.117834_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41594-020-00522-0","article-title":"Mechanism of auto-inhibition and activation of Mec1(ATR) checkpoint kinase","volume":"28","author":"Tannous","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib39","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jmb.2017.04.006","article-title":"Rationally designed PI3Kalpha mutants to mimic ATR and their use to understand binding specificity of ATR inhibitors","volume":"429","author":"Lu","year":"2017","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116167","article-title":"Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase","volume":"267","author":"Alfayomy","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib41","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1021\/acs.jmedchem.9b00426","volume":"62","author":"Knegtel","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/ncb1337","article-title":"ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks","volume":"8","author":"Jazayeri","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11538-021-00868-6","article-title":"ATM and ATR activation through crosstalk between DNA damage response pathways","volume":"83","author":"Fedak","year":"2021","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib44","first-page":"1713","article-title":"ATR and ATRIP: partners in checkpoint signaling","volume":"294","author":"Cortez","year":"2001","journal-title":"Sci. Technol. Humanit."},{"key":"10.1016\/j.ejmech.2025.117834_bib45","article-title":"DNA damage checkpoint kinases in cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117834_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102026","article-title":"ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias","volume":"88","author":"Boudny","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2025.117834_bib47","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/ncb3422","article-title":"Activation of the ATR kinase by the RPA-binding protein ETAA1","volume":"18","author":"Haahr","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100455","article-title":"ATR activation is regulated by dimerization of ATR activating proteins","volume":"296","author":"Thada","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2019.102655","article-title":"Dormant origin signaling during unperturbed replication","volume":"81","author":"Moiseeva","year":"2019","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2025.117834_bib50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12935-020-01304-w","article-title":"The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review","volume":"20","author":"Liu","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2025.117834_bib51","first-page":"806","article-title":"An intrinsic S\/G(2) checkpoint enforced by ATR","volume":"361","author":"Saldivar","year":"2018","journal-title":"Sci. Technol. Humanit."},{"key":"10.1016\/j.ejmech.2025.117834_bib52","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cell.2009.10.015","article-title":"Concerted loading of Mcm2-7 double hexamers around DNA during DNA replication origin licensing","volume":"139","author":"Remus","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib53","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1242\/jcs.096701","article-title":"Controlling DNA replication origins in response to DNA damage - inhibit globally, activate locally","volume":"126","author":"Yekezare","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2025.117834_bib54","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09350","article-title":"Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint","volume":"467","author":"Liu","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117834_bib56","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.apsb.2020.09.007","article-title":"Phosphorylation regulates cullin-based ubiquitination in tumorigenesis","volume":"11","author":"Chen","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117834_bib57","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.cell.2012.03.043","article-title":"Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair","volume":"149","author":"D'Angiolella","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib58","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00294-020-01151-2","article-title":"Budding yeast Rad51: a paradigm for how phosphorylation and intrinsic structural disorder regulate homologous recombination and protein homeostasis","volume":"67","author":"Woo","year":"2021","journal-title":"Curr. Genet."},{"key":"10.1016\/j.ejmech.2025.117834_bib59","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.celrep.2018.08.019","article-title":"ATR-mediated global fork slowing and reversal assist fork traverse and prevent chromosomal breakage at DNA interstrand cross-links","volume":"24","author":"Mutreja","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.117834_bib60","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1101\/gad.214080.113","article-title":"ATR phosphorylates SMARCAL1 to prevent replication fork collapse","volume":"27","author":"Couch","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2025.117834_bib61","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib62","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccr.2012.05.015","article-title":"A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1\/2","volume":"22","author":"Schlacher","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib63","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.molcel.2021.05.027","article-title":"EXO5-DNA structure and BLM interactions direct DNA resection critical for ATR-dependent replication restart","volume":"81","author":"Hambarde","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib64","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1038\/onc.2011.468","article-title":"The RAD9-RAD1-HUS1 (9.1.1) complex interacts with WRN and is crucial to regulate its response to replication fork stalling","volume":"31","author":"Pichierri","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117834_bib65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.molcel.2019.10.008","article-title":"PRIMPOL-mediated adaptive response suppresses replication fork reversal in BRCA-deficient cells","volume":"77","author":"Quinet","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm0314","article-title":"CHK1 phosphorylates PRIMPOL to promote replication stress tolerance","volume":"8","author":"Mehta","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2025.117834_bib67","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.14.4.397","article-title":"ATR disruption leads to chromosomal fragmentation and early embryonic lethality","volume":"14","author":"Brown","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2025.117834_bib68","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0960-9822(00)00447-4","article-title":"Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice","volume":"10","author":"de Klein","year":"2000","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib69","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1038\/s41467-018-07798-3","article-title":"Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA","volume":"9","author":"Menolfi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117834_bib70","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.stem.2007.03.002","article-title":"Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss","volume":"1","author":"Ruzankina","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib71","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ng1129","article-title":"A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome","volume":"33","author":"O'Driscoll","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2025.117834_bib72","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1101\/gad.1067403","article-title":"Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance","volume":"17","author":"Brown","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2025.117834_bib73","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molcel.2015.08.008","article-title":"ATR plays a direct antiapoptotic role at mitochondria, which is regulated by prolyl isomerase Pin1","volume":"60","author":"Hilton","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib74","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fcell.2020.00281","article-title":"Phosphorylation-dependent Pin1 isomerization of ATR: its role in regulating aTR's anti-apoptotic function at mitochondria, and the implications in cancer","volume":"8","author":"Makinwa","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib75","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3389\/fcell.2020.00813","article-title":"PP2A regulates phosphorylation-dependent isomerization of cytoplasmic and mitochondrial-associated ATR by Pin1 in DNA damage responses","volume":"8","author":"Makinwa","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.826576","article-title":"Prolyl isomerization-mediated conformational changes define ATR subcellular compartment-specific functions","volume":"10","author":"Biswas","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib77","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2014.05.046","article-title":"ATR mediates a checkpoint at the nuclear envelope in response to mechanical stress","volume":"158","author":"Kumar","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib78","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1016\/j.molcel.2023.09.023","article-title":"DNA damage induces nuclear envelope rupture through ATR-mediated phosphorylation of lamin A\/C","volume":"83","author":"Kovacs","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib79","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1016\/j.molcel.2023.09.003","article-title":"ATR promotes clearance of damaged DNA and damaged cells by rupturing micronuclei","volume":"83","author":"Joo","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr5683","article-title":"ATR-hippo drives force signaling to nuclear F-actin and links mechanotransduction to neurological disorders","volume":"11","author":"Chatzifrangkeskou","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2025.117834_bib81","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1038\/s41467-018-06556-9","article-title":"ATR\/Chk1 signaling induces autophagy through sumoylated RhoB-mediated lysosomal translocation of TSC2 after DNA damage","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117834_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101668","article-title":"Pharmacological inhibition of ATR can block autophagy through an ATR-independent mechanism","volume":"23","author":"Bowler","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2025.117834_bib83","article-title":"The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4","volume":"349","author":"Kang","year":"2015","journal-title":"Sci. Technol. Humanit."},{"key":"10.1016\/j.ejmech.2025.117834_bib84","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2025.117834_bib85","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117834_bib86","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.1038\/s41598-020-66018-5","article-title":"Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer","volume":"10","author":"Ha","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117834_bib87","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccell.2019.02.004","article-title":"DNA replication vulnerabilities render ovarian cancer cells sensitive to Poly(ADP-Ribose) glycohydrolase inhibitors","volume":"35","author":"Pillay","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117834_bib88","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/ncomms3993","article-title":"Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation","volume":"4","author":"Min","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117834_bib89","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2019.05.009","article-title":"Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies","volume":"201","author":"Murai","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.117834_bib90","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1535-7163.MCT-20-0351","article-title":"Resistance to pyrrolobenzodiazepine dimers is associated with SLFN11 downregulation and can be reversed through inhibition of ATR","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117834_bib91","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41416-020-01199-4","article-title":"SLFN11 informs on standard of care and novel treatments in a wide range of cancer models","volume":"124","author":"Winkler","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117834_bib92","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR inhibition induces CDK1-SPOP signaling and enhances Anti-PD-L1 cytotoxicity in prostate cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000340","article-title":"ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"Sheng","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2025.117834_bib94","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fmolb.2020.00205","article-title":"DNA repair and signaling in immune-related cancer therapy","volume":"7","author":"Kakoti","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2025.117834_bib95","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.AACRAHNS23-PO-085","article-title":"Abstract PO-085: inhibition of ATR as a therapeutic strategy to enhance immunotherapy in head and neck cancer","volume":"29","author":"Osman","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib96","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1172\/JCI96519","article-title":"ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation","volume":"128","author":"Vendetti","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.117834_bib97","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","article-title":"ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment","volume":"25","author":"Dillon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib98","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature23470","article-title":"Mitotic progression following DNA damage enables pattern recognition within micronuclei","volume":"548","author":"Harding","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117834_bib99","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117834_bib100","first-page":"1307","article-title":"Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing","volume":"8","author":"Sun","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib101","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cac2.12412","article-title":"Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer","volume":"43","author":"Liu","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ejmech.2025.117834_bib102","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib103","series-title":"Pyrazine Derivatives Useful as Inhibitors of ATR Kinase and their Preparation and Use in the Treatment of Diseases","author":"Charrier","year":"2010"},{"key":"10.1016\/j.ejmech.2025.117834_bib104","series-title":"Preparation of aminopyrazine-isoxazole Derivatives Useful as Inhibitors of ATR Kinase","author":"Charrier","year":"2013"},{"key":"10.1016\/j.ejmech.2025.117834_bib105","series-title":"Compounds Useful as Inhibitors of ATR Kinase and Combinations Thereof for Treatment of Various Diseases Such as Cancer","author":"Pollard","year":"2013"},{"key":"10.1016\/j.ejmech.2025.117834_bib106","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41416-023-02542-1","article-title":"CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method","volume":"130","author":"Javed","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117834_bib107","doi-asserted-by":"crossref","first-page":"CT115","DOI":"10.1158\/1538-7445.AM2021-CT115","article-title":"Abstract CT115: phase I trial of the triplet berzosertib (M6620, VX-970), veliparib and cisplatin (BVP) in patients with advanced solid tumors","volume":"81","author":"Coyne","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib108","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.117834_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2023.41.16_suppl.4044","article-title":"A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer","volume":"41","author":"Stockton","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117834_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2023.41.16_suppl.5512","article-title":"Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: final overall survival (OS) and biomarker analyses","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117834_bib111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/JCO.2021.39.15_suppl.5034","article-title":"A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer","volume":"39","author":"Choudhury","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117834_bib112","doi-asserted-by":"crossref","first-page":"CT196","DOI":"10.1158\/1538-7445.AM2024-CT196","article-title":"Abstract CT196: first-In-human phase 1\/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors","volume":"84","author":"Simpkins","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib113","series-title":"Morpholinopyrimidines as ATR Kinase Inhibitors and their Preparation, Pharmaceutical Compositions and Use in the Treatment of Cancer","author":"Foote","year":"2011"},{"key":"10.1016\/j.ejmech.2025.117834_bib114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4166","article-title":"DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: a phase 2 trial-in-progress","volume":"39","author":"Yoon","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117834_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2024.42.16_suppl.5510","article-title":"Combination ATR and PARP inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)","volume":"42","author":"Simpkins","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117834_bib116","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117834_bib117","series-title":"HETEROCYCLIC INHIBITORS OF ATR KINASE","author":"Francesco","year":"2019"},{"key":"10.1016\/j.ejmech.2025.117834_bib118","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/j.ygyno.2024.07.443","article-title":"A phase II, open-label, multicenter, basket study of the ATR kinase inhibitor ART0380 administered orally as monotherapy to patients with biologically selected advanced or metastatic solid tumors (ARTIST)","volume":"190","author":"Aghajanian","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117834_bib119","series-title":"Preparation of 2-morpholinopyridine Derivatives as ATR Kinase Inhibitors for the Treatment of Diseases","author":"Crane","year":"2021"},{"key":"10.1016\/j.ejmech.2025.117834_bib120","series-title":"Preparation of pyrrolo[2,3-b]pyridinyl and pyrazolo[3,4-b]pyridinyl Substituted Morpholines as ATR Kinase Inhibitors","author":"Crane","year":"2020"},{"key":"10.1016\/j.ejmech.2025.117834_bib121","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117834_bib122","series-title":"Preparation of Crystal Polymorphic Solid Forms of 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine","author":"Rubenbauer","year":"2018"},{"key":"10.1016\/j.ejmech.2025.117834_bib123","series-title":"2-(Morpholin-4-yl)-1,7-naphthyridines as ATR Inhibitors and their Preparation and Use in the Treatment of Hyperproliferative Diseases","author":"Wortmann","year":"2017"},{"key":"10.1016\/j.ejmech.2025.117834_bib124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-024-04745-6","article-title":"Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)","volume":"95","author":"Krishnamurthy","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117834_bib125","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","article-title":"First-in-Human study of the ataxia telangiectasia and Rad3-Related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors","volume":"30","author":"Yap","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib126","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1158\/1535-7163.MCT-23-0402","article-title":"The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs","volume":"23","author":"Jo","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117834_bib127","series-title":"Preparation of pyrazolo[1,5-a]pyrimidine Carboxamides as Atr Kinase Inhibitors","author":"Ahmad","year":"2014"},{"key":"10.1016\/j.ejmech.2025.117834_bib128","series-title":"Radiolabeled Derivatives of a 2-amino-6-fluoro-I-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide Compound Useful as ATR Kinase Inhibitor, the Preparation of Said Compound and Different Solid Forms Thereof","author":"Ahmad","year":"2015"},{"key":"10.1016\/j.ejmech.2025.117834_bib129","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","article-title":"A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours","volume":"130","author":"Burris","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117834_bib130","series-title":"Preparation of 2-amino-6-fluoro-N-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide Compounds Useful as ATR Kinase Inhibitor, its Preparation, Different Solid Forms and Radiolabelled Derivatives Thereof","author":"Charrier","year":"2015"},{"key":"10.1016\/j.ejmech.2025.117834_bib131","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/cancers10080275","article-title":"The impact of p53 dysfunction in ATR inhibitor cytotoxicity and Chemo- and radiosensitisation","volume":"10","author":"Middleton","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.117834_bib132","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3390\/cancers14040953","article-title":"Everything comes with a price: the toxicity profile of DNA-damage response targeting agents","volume":"14","author":"Martorana","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.117834_bib133","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1182\/blood-2022-169951","article-title":"ATR inhibitor camonsertib (RP-3500) suppresses early stage erythroblasts by mediating ferroptosis","volume":"140","author":"Levy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117834_bib134","first-page":"4375","article-title":"Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine","volume":"59","author":"Sarkaria","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib135","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1254\/jphs.13048FP","article-title":"Differential effect of schisandrin B stereoisomers on ATR-mediated DNA damage checkpoint signaling","volume":"122","author":"Tatewaki","year":"2013","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.117834_bib136","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkp593","article-title":"Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response","volume":"37","author":"Nishida","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib137","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.117834_bib138","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117834_bib140","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1016\/j.bmcl.2017.04.026","article-title":"Sulfoximines as ATR inhibitors: analogs of VE-821","volume":"27","author":"Hendriks","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117834_bib141","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.bmcl.2017.01.045","article-title":"Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR)","volume":"27","author":"Ramachandran","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117834_bib142","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.3390\/molecules27165295","article-title":"Overview of research into mTOR inhibitors","volume":"27","author":"Mao","year":"2022","journal-title":"Molecules (Basel)"},{"key":"10.1016\/j.ejmech.2025.117834_bib143","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117834_bib144","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/cmdc.201700143","article-title":"Targeting DNA-dependent protein kinase for cancer therapy","volume":"12","author":"Harnor","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117834_bib145","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity","volume":"56","author":"Foote","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib146","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1021\/acs.jmedchem.4c00734","article-title":"Discovery of preclinical candidate AD1058 as a highly potent, selective, and brain-penetrant ATR inhibitor for the treatment of advanced malignancies","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib147","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1021\/acs.jmedchem.3c01917","article-title":"Discovery of the potent and selective ATR inhibitor camonsertib (RP-3500)","volume":"67","author":"Black","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib148","doi-asserted-by":"crossref","first-page":"21890","DOI":"10.1021\/acs.jmedchem.4c01595","article-title":"Discovery of ART0380, a potent and selective ATR kinase inhibitor undergoing phase 2 clinical studies for the treatment of advanced or metastatic solid cancers","volume":"67","author":"Carroll","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib149","doi-asserted-by":"crossref","first-page":"13483","DOI":"10.1021\/acs.jmedchem.2c00969","article-title":"Recent scaffold hopping applications in central nervous system drug discovery","volume":"65","author":"Callis","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111691","article-title":"Indole: a privileged scaffold for the design of anti-cancer agents","volume":"183","author":"Wan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib151","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/ml500352s","article-title":"Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors","volume":"6","author":"Barsanti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117834_bib152","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/ml500353p","article-title":"Structure-based drug design of novel potent and selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR inhibitors","volume":"6","author":"Barsanti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117834_bib153","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"Lucking","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib154","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117834_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114187","article-title":"Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: structural activity relationship and antitumor activity both in vitro and in vivo","volume":"232","author":"Bin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib156","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1016\/j.apsb.2022.09.022","article-title":"Harnessing the cyclization strategy for new drug discovery","volume":"12","author":"Tang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117834_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114945","article-title":"Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design","volume":"246","author":"Qi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106535","article-title":"Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors","volume":"136","author":"Duan","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib159","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.3390\/molecules28114521","article-title":"Design, synthesis, and biological evaluation of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase for the efficient treatment of cancer","volume":"28","author":"Shao","year":"2023","journal-title":"Molecules (Basel)"},{"key":"10.1016\/j.ejmech.2025.117834_bib160","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tips.2021.04.001","article-title":"Fragment-based drug design facilitates selective kinase inhibitor discovery","volume":"42","author":"Wang","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.117834_bib161","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1021\/acs.jmedchem.5c00424","article-title":"Fragment-based drug design: from then until now, and toward the future","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115370","article-title":"Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase","volume":"255","author":"Duan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib163","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1021\/acs.jmedchem.4c02380","article-title":"Discovery of the clinical candidate YY2201 as a highly potent and selective ATR inhibitor","volume":"68","author":"Wu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib164","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1038\/onc.2012.462","article-title":"ATR controls cellular adaptation to hypoxia through positive regulation of hypoxia-inducible factor 1 (HIF-1) expression","volume":"32","author":"Fallone","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117834_bib165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000991","article-title":"Phosphorylation of seryl-tRNA synthetase by ATM\/ATR is essential for hypoxia-induced angiogenesis","volume":"18","author":"Shi","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib166","article-title":"Hypoxia-responsive prodrug of ATR inhibitor, AZD6738, selectively eradicates treatment-resistant cancer cells","volume":"11","author":"Barnieh","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ejmech.2025.117834_bib167","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117834_bib168","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/leu.2017.207","article-title":"BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117834_bib169","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117834_bib170","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1038\/s41467-021-24217-2","article-title":"ATR regulates neuronal activity by modulating presynaptic firing","volume":"12","author":"Kirtay","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117834_bib171","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1038\/s41467-020-18580-9","article-title":"ATR is essential for preservation of cell mechanics and nuclear integrity during interstitial migration","volume":"11","author":"Kidiyoor","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117834_bib172","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/1878-0261.13638","article-title":"Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells","volume":"18","author":"Kansy","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117834_bib173","article-title":"Discovery of selective and potent ATR degrader for exploration its kinase-independent functions in acute myeloid leukemia cells","volume":"63","author":"Wang","year":"2024","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2025.117834_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116159","article-title":"Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment","volume":"267","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib175","article-title":"Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy","volume":"1878","author":"Ye","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2025.117834_bib176","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117834_bib177","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3390\/molecules23050992","article-title":"Design, synthesis, and docking studies of new Torin2 analogs as potential ATR\/mTOR kinase inhibitors","volume":"23","author":"Shaik","year":"2018","journal-title":"Molecules (Basel)"},{"key":"10.1016\/j.ejmech.2025.117834_bib178","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1021\/acsomega.2c07356","article-title":"Exploring SPK98 for the selective sensitization of ATM- or P53-Deficient cancer cells","volume":"8","author":"Priya","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.117834_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127517","article-title":"Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor","volume":"30","author":"Bhakuni","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117834_bib180","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1021\/acs.jmedchem.1c01999","article-title":"Discovery of dual TAF1-ATR inhibitors and ligand-induced structural changes of the TAF1 tandem bromodomain","volume":"65","author":"Karim","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib181","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1182\/blood-2024-207718","article-title":"YL0712-3, a novel ATR\/ATM inhibitor, demonstrates anti-tumor activity in TP53 mutant DLBCL through synthetic lethality and degradation of mutant p53","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117834_bib182","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2006.01.026","article-title":"The role of NBS1 in the modulation of PIKK family proteins ATM and ATR in the cellular response to DNA damage","volume":"243","author":"Zhou","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.117834_bib183","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/jphp.12393","article-title":"Low solubility in drug development: de-convoluting the relative importance of solvation and crystal packing","volume":"67","author":"Docherty","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117834_bib184","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/jm101356p","article-title":"Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry","volume":"54","author":"Ishikawa","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117834_bib185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/138920011794520044","article-title":"Role of cyclic tertiary amine bioactivation to reactive iminium species: structure toxicity relationship","volume":"12","author":"Masic","year":"2011","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.ejmech.2025.117834_bib186","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/03602532.2014.924962","article-title":"Biotransformation and bioactivation reactions of alicyclic amines in drug molecules","volume":"46","author":"Bolleddula","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejmech.2025.117834_bib187","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1073\/pnas.1522080113","article-title":"Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy","volume":"113","author":"Li","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.117834_bib188","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1180794","article-title":"Cell- and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy","volume":"14","author":"Wei","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117834_bib189","doi-asserted-by":"crossref","first-page":"23223","DOI":"10.1021\/acsnano.3c06019","article-title":"Stimuli-responsive polymer-based nanosystems for cancer theranostics","volume":"17","author":"Wei","year":"2023","journal-title":"ACS Nano"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T08:38:36Z","timestamp":1754987916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425005999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":188,"alternative-id":["S0223523425005999"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117834","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A medicinal chemistry perspective on ATR: Current status and future directions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117834"}}